Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 712737 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
EnterprisewideAdd to Basket
EnterprisewideAdd to Basket
Electronic (Online Access)Add to Basket
Hard CopyAdd to Basket
Electronic (PDF)Add to Basket
Live Chat Live Help Software for Website

The Pharmaceutical Market: Portugal

Espicom Business Intelligence Ltd, Oct 2011, Pages: 72


  Description  
   Table of Contents   
   Companies Mentioned   
    
    
     
  Enquire before Buying   
  Send to a Friend   

THE PHARMACEUTICAL MARKET: PORTUGAL - REVIEW

The macroenvironment remains tough for the Portuguese pharmaceutical market. Politically, the new Prime Minister aims to create a more efficient state and comply with the bail-out commitments signed by the previous socialist government. The austerity programme is expected to remain high on his agenda. Economically, the Economist Intelligence Unit (EIU) believes that economic and fiscal policy will be shaped by the bail-out agreement signed with the EU and the IMF. There are signs that public hospitals will be affected as part of the country’s effort to reduce its budget deficit. Legally, IPR regulations are harmonised with EU procedures. Demographically, Portugal has one of the smallest population in Western Europe, but the EIU projects that the number of people aged 65 years and over will increase to represent 18.8% of the total population in 2016, equal to 2.0 million people.

Pharmaceutical sales growth will be negligible in the forecast period. In US dollar terms, pharmaceutical sales in Portugal are expected to rise in 2011, due to a weaker exchange of the US dollar against the euro, and to fall between 2012 and 2016, affected by a stronger projected exchange rate. In euro terms, pharmaceutical sales are projected to increase modestly in the forecast period, due to the government’s cost-containment measures. In 2016, the Portuguese pharmaceutical market will be one of the smallest in Western Europe, ranking 12th. In per capita terms, Portugal will have the lowest pharmaceutical expenditure. The new Minister of Health is very keen to encourage further generic consumption, with a new proposal submitted in September 2011.

Improved regulation has encouraged generic sales in Portugal, but prices have been slashed in recent years. Generic sales rose by 4.5% in local terms in 2010, and recorded a market share of 19.1%. In volume terms, generic sales rose by 10.9% in 2010, and recorded a market share of 18.3%; contrary to what happens in other markets, generics sales in Portugal have a higher market share in value than in volume. The generic market is very fragmented, with many companies that have a low market share. Leading national generic producers include Farmoz (part of Tecnimede), Generis (part of Farma-APS), Medinfar, Hovione, Bluepharma and ToLife. Foreign generic producers include Mylan, ratiopharm (now part of Teva), Alter, Fresenius Kabi (via Labesfal) Stada, Actavis and Winthrop.

ENHANCED STRATEGIC INTELLIGENCE

These highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context. The reports provide:

- Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
- Specialised intelligence on OTCs, generics, biologics and biosimilars.
- Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
- A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
- The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

HEALTHCARE STATISTICS

A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.



Customers who bought this item also bought

The Pharmaceutical Market: Pakistan

The Pharmaceutical Market: Ukraine

The Pharmaceutical Market: Canada

The Pharmaceutical Market: Thailand

The Pharmaceutical Market: Greece

The Pharmaceutical Market: Croatia

The Pharmaceutical Market: Australia

The Pharmaceutical Market: Israel

The Pharmaceutical Market: Austria

The Pharmaceutical Market: Bangladesh



For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-800-526-8630 (US/Canada Toll Free)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds